𝔖 Bobbio Scriptorium
✦   LIBER   ✦

De novo renal cell carcinoma of native kidney in renal transplant recipients

✍ Scribed by Yann Neuzillet; Franck Lay; Aline Luccioni; Laurent Daniel; Yvon Berland; Christian Coulange; Eric Lechevallier


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
81 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

The 10‐year risk of developing a solid malignancy is 20% for kidney transplant recipients. The goal of the current study was to investigate the epidemiology and the diagnostic and prognostic parameters associated with de novo malignancies of the native kidney among transplant recipients at the authors' institution (Department of Urology and Renal Transplantation, Hôpital Salvator, Marseille, France).

METHODS

The authors reexamined the follow‐up of 933 consecutive transplant recipients at their institution between 1987 and 2003. Immunossupressive therapy was not modified in the event of malignant disease, nor was systematic radiologic monitoring of native kidneys performed. All de novo malignancies of the native kidney were included in the current analysis.

RESULTS

Among the 933 patients examined, a combined total of 12 malignancies of the native kidney were diagnosed in 11 individuals. For these 11 individuals, the average ages at transplantation and diagnosis were 42.5 and 49.1 years, respectively. Ten malignancies were discovered fortuitously, whereas two were symptomatic. Among the 10 renal echographies performed, there was 1 false‐negative result. Tomodensitometry was performed in 11 cases and yielded no false‐negative results. The average tumor size was 37 mm. Nephrectomy was performed in 10 cases, and biopsy was performed in 1. Among the 12 kidney malignancies encountered in the current study, there were 7 conventional cell carcinomas, 3 basophilic papillary carcinomas, and 2 chromophobic renal cell carcinomas. Half of all tumors were Furhman Grade 3 lesions, and pT1aN0M0 tumors (2003 TNM staging system) also accounted for half of all malignancies in the current cohort. Two affected transplant recipients died (one due to disease), and the remaining nine are alive without recurrence and with normal renal functioning (median follow‐up, 39 months).

CONCLUSIONS

There appears to be an increased risk of malignancy of the native kidney in renal transplant recipients, with high‐grade and papillary tumors being particularly common. Consequently, systematic radiologic follow‐up of native kidneys must be performed for individuals who undergo kidney transplantation. Cancer 2005. © 2004 American Cancer Society.


📜 SIMILAR VOLUMES


Early detection of hepatocellular carcin
✍ Tang, S.; Lo, C. M.; Chan, T. M.; Lai, K. N. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 2 views

Hepatocellular carcinoma (HCC) is a leading cause of malignancy after renal transplantation in Asia, where hepatitis B virus infection is endemic. Early detection and resection are the key to successful treatment because the mortality rate for HCC is high. The value of ␣-fetoprotein monitoring in th

Evolution of hepatitis C virus quasispec
✍ Nassim Kamar; Lionel Rostaing; Anne Boulestin; Karine Sandres; Martine Dubois; D 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract Long‐term renal allograft survival in kidney transplant recipients infected by hepatitis C virus (HCV) may be influenced by the occurrence of de novo glomerulopathy associated with this virus. Therefore, we studied the evolution of HCV quasispecies in kidney transplant recipients infect

Improved patient survival in recipients
✍ P. Mohan; K. Safi; D. M. Little; J. Donohoe; P. Conlon; J. J. Walshe; P. O'Kelly 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## Abstract ## Background There are emerging data that simultaneous pancreas–kidney transplant (SPK) prolongs life compared with kidney transplant alone (KTA) in type 1 diabetics with end-stage renal disease. This study was a retrospective comparison of SPK with KTA in patients with type 1 diabete